dalteparin has been researched along with Cancer of Endometrium in 6 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "All patients with newly diagnosed endometrial cancer who underwent minimally invasive staging surgery from January 1, 2017 to December 31, 2020 were identified retrospectively, and clinicopathologic and outcome data were obtained through chart review." | 1.91 | Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis. ( Bell, S; Berger, J; Garrett, A; Kim, H; Lesnock, J; Orellana, T; Rosiello, A; Rush, S; Smith, K, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, R | 1 |
| Nansubuga, F | 1 |
| Yang, J | 1 |
| Ding, W | 1 |
| Li, K | 1 |
| Weng, D | 1 |
| Wu, P | 1 |
| Chen, G | 1 |
| Ma, D | 1 |
| Wei, J | 1 |
| Palmieri, A | 1 |
| Hicks, V | 1 |
| Aikman, N | 1 |
| Borowsky, M | 1 |
| Haggerty, A | 1 |
| ElSahwi, K | 1 |
| Bell, S | 1 |
| Orellana, T | 1 |
| Garrett, A | 1 |
| Smith, K | 1 |
| Kim, H | 1 |
| Rosiello, A | 1 |
| Rush, S | 1 |
| Berger, J | 1 |
| Lesnock, J | 1 |
| Carbajal-Mamani, SL | 1 |
| Dideban, B | 1 |
| Schweer, D | 1 |
| Balavage, KT | 1 |
| Chuang, L | 1 |
| Wang, Y | 1 |
| Wang, S | 1 |
| Lee, JH | 1 |
| Amaro, B | 1 |
| Cardenas-Goicoechea, J | 1 |
| Tadic, M | 1 |
| Belyavskiy, E | 1 |
| Cuspidi, C | 1 |
| Pieske, B | 1 |
| Haßfeld, S | 1 |
| Garcipérez de Vargas, FJ | 1 |
| Marcos, G | 1 |
| Moyano Calvente, SL | 1 |
1 trial available for dalteparin and Cancer of Endometrium
| Article | Year |
|---|---|
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, L | 2020 |
5 other studies available for dalteparin and Cancer of Endometrium
| Article | Year |
|---|---|
Extended Venous Thromboembolism Prophylaxis after Robotic Staging for Endometrial Cancer.
Topics: Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Humans; Postoperative Complications; Retr | 2023 |
Prophylactic anticoagulation after minimally invasive hysterectomy for endometrial cancer: a cost-effectiveness analysis.
Topics: Anticoagulants; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Endometrial Neoplasms; Enoxapari | 2023 |
Incidence of venous thromboembolism after robotic-assisted hysterectomy in obese patients with endometrial cancer: do we need extended prophylaxis?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Endometrial Neoplasms; Enoxaparin; Female; Heparin; | 2021 |
Right heart masses in a patient with endometrial stromal sarcoma.
Topics: Echocardiography; Endometrial Neoplasms; Enoxaparin; Female; Fibrinolytic Agents; Heart Diseases; Hu | 2020 |
Pulmonary embolism as a first manifestation of intracardiac extension of an endometrial stromal sarcoma.
Topics: Anticoagulants; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Endometrial Neoplasms; E | 2014 |